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In recent years there has been an increasing interest in
measuring health-related quality of life (HRQoL) with
instruments such as the SF-36. OBJECTIVES: The aim of
this study is to examine the relationship between SF-36
and socio-demographic factors in a general population
sample. We especially focus on differences between men
and women. METHODS: Data was based on a postal
questionnaire sent to a random sample of 8000 inhabit-
ants (response rate 68%) in Uppsala County, Sweden, in
1995. RESULTS: Women reported lower scores than
men on all eight dimensions of SF-36. Physical health
was lower among the older for both men and women.
Mental health was approximately constant with age for
men and slightly higher among older women. Both physi-
cal and mental health were higher among those with
higher education, income and social group. When con-
trolling for the other variables education was not related
to physical and mental health and social group was only
related to physical health. The association of higher men-
tal health scores for those with higher income was stron-
ger for men than for women. Unemployment was associ-
ated with lower mental health, but was not related to
physical health after controlling for the other variables.
The association of unemployment with mental health
was larger for men than for women. Physical health did
not vary with marital status, but for mental health the
scores were lower for persons that are single, divorced or
widows compared to married persons. CONCLUSIONS:
Our results indicate that inequalities in HRQoL are
present with respect to several socioeconomic variables.
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The statistical significance of a phase-III clinical trial will
guide clinical treatment in practice. However, the clinical
trial-based strategy for treatment could be contaminated
by the statistical errors. OBJECTIVES: The study pur-
pose was to formulate the influence of the statistical er-
rors on the cost-effectiveness of the subsequent treatment
strategy based on the result of a phase-III clinical trial.
METHODS: Consider a clinical trial for the two regi-
mens: a new treatment A (TA) and an old treatment B
(TB). Assuming the truth is that TA is more effective than
TB, consider the subsequent three rational scenarios: 1)
no significant difference between TA and TB with the type
II error (), then regard TA and TB as equivalent, 2) prefer
TB to TA with the type III error (), and 3) prefer TA to TB
with the other probability (1--). Then the cost-effec-
tiveness of the scenarios was theoretically evaluated in
use of decision-analytic modeling. RESULTS: Using the
variables  and , the mathematical formula which esti-
mates the cost-effectiveness ratio of the treatment model
was proven to show an intermediate value between the
cost-effectiveness ratios for TA and TB given in the phase-
III clinical trial. If the type II error decreases, the subse-
quent cost-effectiveness ratio approaches to the better
cost-effectiveness ratio given in the phase-III clinical trial.
CONCLUSIONS: It was theoretically proven that ratio-
nal treatment strategy according to the result of a phase-
III clinical trial can improve the cost-effectiveness within
the certain range even if the type II and the type III errors
exist.
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Transforming generic HRQOL instruments to a sum-
mary utility index is useful for deriving quality adjusted
life years (QALY) in any cost/QALY analysis. Neverthe-
less, relatively little research has been done to map or re-
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value generic HRQOL measures to utility scores. OB-
JECTIVE: The purpose of this study was to investigate
the role of the SF-12 in predicting utility scores derived
from Health Utility Index (HUI) and Visual Analogue.
METHOD: Data were obtained from 6000 randomly se-
lected managed care patients aged 25 to 95 years in the
US. The SF-12, HUI-III and VAS were used in the survey
to assess health status. The SF-12 items were used to pre-
dict HUI and VAS scores using least square regression,
with disease and sociodemographic covariates. A second
model entered each SF-12 item as categorized responses
to avoid any arbitrary assumption about the differences
in quality of life between different item response alterna-
tives in the SF-12. Model heteroscedasticity was cor-
rected by White variance-covariance matrix. A bounded
‘Influence Estimation’ procedure was also used to cap-
ture the effect of any extreme utility score. RESULTS:
The SF-12 items and socio- demographic covariates ac-
counted for 47% to 52% of the variations in the HUI-III
and VAS. Age and items of the SF-12 were significantly
(P  0.05) associated with variations in utility scores.
Model specification satisfied the RESET test and the lin-
ear model showed a favorable result compared to the log-
log or semi-log model. CONCLUSIONS: This research
provides support that an algorithm can be derived from
the SF-12 to predict HUI and VAS, and thus utility
scores. This is also consistent with the previous findings
on predictive algorithms using the SF-36 and HUI to de-
rive utility scores.
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Most studies in the area of quality of life have either a
health profile such as the SF-36 scores or the Quality Ad-
justed Life Years (QALYs), as the outcome of interest.
However in using one type of measure, valuable informa-
tion that can be derived from the other type of measure is
not available. OBJECTIVES: The purpose of this study
was to derive QWB scores from the SF-36 scores and
thereby calculate the QALY. METHODS: Patients with
3 specific medical conditions were selected from the
Idaho Medicaid population. The subjects were randomly
selected within each disease state and were sent a mail
version of the SF-36 questionnaire. Using the regression
equation developed in the Beaver Dam Health Outcomes
Study, the QWB scores were calculated from the SF-36
scores. The QWB scores were then used in calculating the
QALYs for the respondents. RESULTS: The response
rate for the survey was 20%. Using an ANOVA analysis
the study found the cost to produce one QALY was sig-
nificantly different, with P  0.009 for patients with dif-
ferent medical conditions. In the treatment of hyperten-
sive patients, the cost to produce one QALY differed
significantly (P  0.004) for patients on different treat-
ments. In the treatment of congestive heart failure pa-
tients, the cost to produce one QALY differed signifi-
cantly (P  0.021) for patients on different treatments.
CONCLUSIONS: Patients with different medical condi-
tions would need varying amounts of resources to
achieve a comparable level of quality of life. This is also
true for patients on different treatments. The findings
would be an aid in allocation of resources between medical
conditions and between treatments within a disease state.
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BACKGROUND: Expert panel data are often used to
collect resource use, effectiveness, and quality of life data
when alternative methods are impractical due to cost,
timing, or for ethical reasons. OBJECTIVE: To compare
several methods of deriving EQ-5D valuations from expert
panel data. METHODS: A panel of 7 physicians pro-
vided EQ-5D valuations for 5 health states associated
with atrial fibrillation: (State 1) Well in atrial fibrillation;
(State 2) Minor disability in normal sinus rhythm; (State
3) Minor disability in atrial fibrillation; (State 4) Major
disability in atrial fibrillation; (State 5) Major disability
in normal sinus rhythm. Three methods of combination
were used to estimate utilities: a) averaging calculated
utility scores b) the modal dimension valuation c) the
modal overall valuation. The resulting utility weights for
each method were compared across health states, and on
internal consistency (expected ordering of the health
states as above). RESULTS: The valuations from the
methods were similar within states for State 1 (0.85 to
0.86), State 3 (0.49 to 0.52) and State 5 (0.07 to
0.09), but disparate utilities resulted for State 2 (0.52
to 0.66) and State 4 (0.17 to 0.52). The averaging and
modal dimension methods gave the expected ordering.
The modal dimension method, however, estimated a very
large step (i.e., 0.68) in utility between states of major
disability. The averaging method gave results that were
the most linear between states. CONCLUSIONS: Lack of
a gold standard methodology makes synthesizing expert
panel utility valuations problematic. In this instance, av-
eraging gave results consistent with expected ordering
and with no unexpected large drops in utility.
